PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
40.22%
Revenue growth above 1.5x CVE's 4.28%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
145.91%
Gross profit growth above 1.5x CVE's 35.57%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
94.03%
EBIT growth above 1.5x CVE's 12.88%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
94.03%
Operating income growth above 1.5x CVE's 12.88%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
16.06%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
16.00%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
16.00%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.03%
Share reduction while CVE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Dividend growth of 0.03% while CVE is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
80.98%
OCF growth above 1.5x CVE's 6.30%. David Dodd would confirm a clear edge in underlying cash generation.
318.67%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
-26.89%
Negative 10Y revenue/share CAGR while CVE stands at 44.01%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-81.46%
Negative 5Y CAGR while CVE stands at 44.01%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-73.05%
Negative 3Y CAGR while CVE stands at 44.01%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
232.03%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-47.72%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-56.79%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-1358.85%
Negative 10Y net income/share CAGR while CVE is at 184.43%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-234.80%
Negative 5Y net income/share CAGR while CVE is 184.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5178.11%
Negative 3Y CAGR while CVE is 184.43%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-14.95%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-71.85%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-77.43%
Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
352.84%
Dividend/share CAGR of 352.84% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-0.69%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-49.99%
Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-6.11%
Firm’s AR is declining while CVE shows 23.63%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-63.93%
Inventory is declining while CVE stands at 7.58%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.80%
Negative asset growth while CVE invests at 7.09%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-19.25%
We have a declining book value while CVE shows 0.93%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.35%
Debt shrinking faster vs. CVE's 23.52%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
7.37%
SG&A declining or stable vs. CVE's 82.46%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.